Indapamide-induced hyponatremia or the syndrome of inappropriate antidiuretic hormone secretion: a case report

[1] Hannon M, Thompson C. SIADH: Prevalence, causes and consequences. Eur J Endocrinol. 2010; 162: S5–S12 http://dx.doi.org/10.1530/EJE-09-106310.1530/EJE-09-1063Search in Google Scholar

[2] Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342(21):1581–1589 http://dx.doi.org/10.1056/NEJM20000525342210710.1056/NEJM200005253422107Search in Google Scholar

[3] Biswas M, Davies JS. Hyponatremia in clinical practice. Postgrad Med J. 2007 Jun;83(980):373–378. Witek P. Progress in diagnosis and treatment of hyponatremia. Postepy Nauk Medycznych 2008; (2): 75–82 http://dx.doi.org/10.1136/pgmj.2006.05651510.1136/pgmj.2006.056515Search in Google Scholar

[4] Gill G, Leese G. Hyponatremia: biochemical and clinical perspectives. Postgrad Med J. 1998; 74(875):516–523 http://dx.doi.org/10.1136/pgmj.74.875.51610.1136/pgmj.74.875.516Search in Google Scholar

[5] Krysiak R, Okopień B. Carbamazepine-induced hyponatremia. Pol. Arch. Med. Wew. 2007; 117: 193–195 Search in Google Scholar

[6] Verbalis JG, Drutarosky MD, Ertel RJ, Vollmer RR. Adaptive responses to sustained volume expansion in hyponatraemic rats. J Endocrinol. 1989; 122(1):421–431 http://dx.doi.org/10.1677/joe.0.122042110.1677/joe.0.1220421Search in Google Scholar

[7] Morledge JH. Clinical efficacy and safety of indapamide in essential hypertension. Am Heart J. 1983; 106(1 Pt 2):229–232 http://dx.doi.org/10.1016/0002-8703(83)90121-710.1016/0002-8703(83)90121-7Search in Google Scholar

[8] PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358(9287):1033–1041 http://dx.doi.org/10.1016/S0140-6736(01)06178-510.1016/S0140-6736(01)06178-5Search in Google Scholar

[9] Piotrowski W, Włodarczyk P, Jasiński B, Rywik S. Efficacy and Acceptability of the Indapamide SR 1,5 mg (Tertensif® SR) in Patients above 55 Years of Age with Isolated Systolic Hypertension — the STIP Study. Nadciśnienie Tętnicze. 2001; 5(4): 245–252 Search in Google Scholar

[10] Leonetti G. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension. Drugs. 2000;59(Suppl 2):27–38; discussion 39–40 http://dx.doi.org/10.2165/00003495-200059002-0000410.2165/00003495-200059002-00004Search in Google Scholar

[11] Kuo SW, Pei-Dee, Hung YJ, Hsieh AT, Wu LY, Hsieh CH, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens. 2003;16(8):623–628 http://dx.doi.org/10.1016/S0895-7061(03)00896-310.1016/S0895-7061(03)00896-3Search in Google Scholar

[12] Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatremia and hypokalaemia due to indapamide. Med J Aust. 2002; 176(5):219–221 10.5694/j.1326-5377.2002.tb04377.xSearch in Google Scholar PubMed

[13] Hamano T, Yamamoto T, Miyamori I, Kuriyama M. Hyponatremia with somnolence due to indapamide. Rinsho Shinkeigaku. 2008;48(1):52–55 10.5692/clinicalneurol.48.52Search in Google Scholar PubMed

[14] Chan TY. Indapamide-induced severe hyponatremia and hypokalemia. Ann Pharmacother. 1995;29(11):1124–1128 10.1177/106002809502901111Search in Google Scholar PubMed

[15] Cabaj-Wiater I, Jakubowska I. Hyponatremia in Syndrome of Inappropiate Antidiuretic Hormone Secretion — cases report. Pol. Merk. Lek., 2008, 147: 247–249 Search in Google Scholar

[16] Howes L. Hyponatremia and hypokaliemia caused by indapamide. The medical Journal of Australia. 2002; 176(12): 53–54 10.5694/j.1326-5377.2002.tb04578.xSearch in Google Scholar PubMed